Pharmacogenomic heterogeneity of <i>N-acetyltransferase 2</i> : a comprehensive analysis of real world data in Indian tuberculosis patients and from literature and database review

BACKGROUND: SNPs and the slow acetylator phenotype have been implicated as risk factors for the development of antitubercular drug-induced liver injury (AT-DILI) in several tuberculosis (TB) populations. PATIENTS AND METHODS: pharmacogenomic profile of patients from these regions was compared with the reports from several geographically diverse TB populations and participants of different genetic ancestries extracted from literature reviews and the 'All of Us' Research Program database, respectively. RESULTS: slow acetylators, among whom a relatively higher proportion experienced AT-DILI. CONCLUSION: genotyping as a pre-emptive biomarker for AT-DILI monitoring for personalized isoniazid therapy in clinics.